CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 81,395	$ 90,326
Accounts receivable, net	299,983	269,312
Inventories	211,644	195,019
Other current assets	128,329	124,982
Total current assets	721,351	679,639
Long-Term Assets:
Property and equipment, net	546,158	533,845
Operating lease right-of-use assets	78,612	80,607
Goodwill	233,211	239,724
Intangible assets, net	57,948	58,468
Other long-term assets	248,965	240,192
Total long-term assets	1,164,894	1,152,836
TOTAL ASSETS	1,886,245	1,832,475
Current Liabilities:
Accounts payable	74,210	72,172
Accrued liabilities	247,179	322,938
Line of credit	486,824	288,765
Current portion of deferred revenue	38,028	41,462
Total current liabilities	846,241	725,337
Long-Term Liabilities:
Deferred income tax liabilities	38,908	33,024
Long-term debt	697,363	698,910
Long-term deferred revenue, net of current portion	49,042	48,743
Long-term operating lease liabilities	65,343	67,472
Other long-term liabilities	81,293	81,164
Total long-term liabilities	931,949	929,313
Total liabilities	1,778,190	1,654,650
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 105,914 shares in 2020 and 105,711 shares in 2019; Outstanding: 84,929 shares in 2020 and 85,471 shares in 2019	10,591	10,571
Additional paid-in capital	1,230,485	1,213,517
Deferred stock units: Outstanding: 144 units in 2020 and 143 units in 2019	4,508	4,462
Retained earnings	1,705,646	1,595,648
Accumulated other comprehensive loss	(55,246)	(46,182)
Treasury stock, at cost: 20,985 shares in 2020 and 20,240 shares in 2019	(2,788,310)	(2,600,543)
Total IDEXX Laboratories, Inc. stockholders’ equity	107,674	177,473
Noncontrolling interest	381	352
Total stockholders’ equity	108,055	177,825
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 1,886,245	$ 1,832,475